SpaceX plans Starship program for in-orbit drug research - Bloomberg

Published 15/07/2025, 18:16
© Reuters

Investing.com -- SpaceX is developing a program to utilize its Starship rocket for commercial product development in space, potentially creating a new revenue stream for the company.

The program, internally named Starfall, would transport items such as pharmaceutical components to space in small, uncrewed capsules aboard the Starship rocket, according to Bloomberg, citing people familiar with the matter who requested anonymity due to the confidential nature of the plans.

After reaching orbit, Starship would deploy these capsules, which would remain in space for a period before returning to Earth’s atmosphere where they could be recovered.

Starfall aims to leverage the unique conditions of space, particularly micro-gravity and elevated radiation levels, which create distinctive environments for manufacturing pharmaceutical drugs, semiconductors, food products, and cosmetics.

This initiative could represent a significant business expansion for SpaceX, which is currently the world’s most valuable private startup.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.